Equillium, Inc. Aktie News

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates.

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.

Equillium, Inc. secured up to $50 million in funding to advance EQ504, its novel AhR modulator, for ulcerative colitis treatment. A phase 1 proof-of-concept study for EQ504 in ulcerative colitis is set to begin in mid-2026, with early data expected within six months afterwards. EQ504's mechanism is validated by Tapinarof's approval in skin disorders, supporting its potential in both gastrointes...

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equill...

LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. “As we are actively evaluating strategic options for the compan...